Data are available from the MRC Clinical Trials Unit at UCL for researchers who meet the criteria for access to confidential data. The data are freely available from the Principal Investigator, Professor Kholoud Porter (<Kholoud.porter@ucl.ac.uk>), to whom all such requests should be made.

Introduction {#sec005}
============

At 37.1 per 100,000, Ukraine has one of the highest HIV diagnosis rates in Europe during 2012 \[[@pone.0137062.ref001]\] and estimated adult prevalence of 1.1% \[[@pone.0137062.ref002]\]. Although the first HIV report was in 1987, the majority of diagnoses of HIV were made from 1995 onwards \[[@pone.0137062.ref003]\] and, by 2009, the number diagnosed was more than double that of 2001 \[[@pone.0137062.ref002]\], with yearly diagnosis rates rising from 12.5 per 100,000 population in 2001 \[[@pone.0137062.ref004]\] to 37.1 in 2012 \[[@pone.0137062.ref001]\].

Instrumental to this rapid increase was injecting drug use, with outbreaks of HIV initially identified in the southern regions of Odessa and Mykolaiv among people who inject drugs (PWID) \[[@pone.0137062.ref005]--[@pone.0137062.ref007]\]. However, in more recent years HIV infection attributable to sexual transmission has increased with the number of diagnoses reported to be due to sex between men and women overtaking that among PWID \[[@pone.0137062.ref003]\]. A suggested reason for this increase is the bridging between PWID and the heterosexual population through male injecting drug users transmitting to their female sexual partners \[[@pone.0137062.ref008]\].

Furthermore, men who have sex with men (MSM) and commercial sex workers (CSW) \[[@pone.0137062.ref009]\] are part of a *'hidden epidemic'*. In particular, MSM as a group, are subject to stigma and discrimination \[[@pone.0137062.ref003], [@pone.0137062.ref010]\], with Ukraine recently considering following the Russian anti-propaganda bill against distributing information on non-traditional sexual attitudes \[[@pone.0137062.ref011], [@pone.0137062.ref012]\]. Such acts make MSM less likely to identify as such \[[@pone.0137062.ref009]\], making appropriate targeted public health interventions problematic. Based on published literature, including the European MSM internet survey (EMIS) (0.3%) \[[@pone.0137062.ref013]\], and work by AIDS Alliance using a social network scale-up method, population surveys and estimates from other countries (0.9%) \[[@pone.0137062.ref014]\], estimates of MSM living in Ukraine ranged from 62,888 to 198,470. Further, a sentinel study in 2011 interviewing 5950 MSM from all regions of Ukraine, estimated an overall prevalence of 6.4%, ranging from 2% in Mykolayiv to 20% in Donetsk \[[@pone.0137062.ref015]\]. Yet only 152 of 16,872 new HIV diagnoses in 2012 were reported to be among MSM \[[@pone.0137062.ref001]\], a considerable under-estimate if the aforementioned figures are to be believed.

In line with WHO testing guidelines \[[@pone.0137062.ref016]\], free and confidential testing for HIV is accessible nationwide, with service-initiated screening also available in antenatal settings, prisons, blood donor facilities and for policy and regulation reasons. In 2012, just over 2 million tests were conducted in Ukraine overall, a 49% increase on the 1.5 million reported in 2004 \[[@pone.0137062.ref001]\].

In this study, we sought to collect more information than is currently available about persons presenting for an HIV test in the main testing centres of the Ukrainian capital Kiev, to establish the feasibility of collecting such data, and estimate HIV testing rates, positivity rates, and characterise those at risk of HIV. These data are helpful to healthcare planners and, in particular, for the design of appropriately-targeted healthcare interventions. They are also needed as part of a larger study to estimate HIV incidence within that region.

Methods {#sec006}
=======

In April 2013 we introduced new methodology for data collection of persons presenting for an HIV test at the main testing facilities within the City of Kiev, to characterise populations at risk. These testing facilities consisted of four infectious disease clinics for HIV, collectively known as the Kiev City AIDS Centre.

All adults (≥16years) presenting or referred for an HIV test at the Kiev City AIDS Centre, between April 1^st^ 2013 and March 31^st^ 2014 were included. Persons testing as part of antenatal or blood donation screening were excluded, as different methodologies for estimating HIV incidence are required for these populations, given that population sizes for these groups are known.

At the time of an individual's initial HIV test, limited information is usually collected by the healthcare provider seeking input from the attendee. Such information included: identification number, year of birth, residence and reason for test, but no information on probable route of exposure is explicitly sought. Working with the non-governmental organisation Perinatal Prevention of AIDS Initiative (PPAI) and the AIDS centre, we introduced a short anonymous questionnaire to be completed at the time of testing by the clinic attendee using a handheld electronic tablet. Medical staff completed year of birth, sex and identification number before passing the electronic tablet to the attendee. A short explanation about the questionnaire was provided and patients were asked to give their consent to continue or to terminate the session. A set of four short questions followed asking information on residence, risk factors for acquiring HIV, reason for test and testing history. The electronic tablet was chosen to ensure persons felt comfortable with disclosing high risk behaviours and maintain anonymity.

Ethics statement {#sec007}
----------------

The study was part of CASCADE within EuroCoord ([www.EuroCoord.net](http://www.EuroCoord.net)) funded by the European Union Framework Programme VII. Ethics approval was given by the ethics committee of the Institute of Epidemiology and Infectious Diseases, Academy of Medical Sciences of Ukraine, Kiev, Ukraine and the ethics committee of University College London (UCL). The study was an extension of the current routine surveillance methods already defined in Kiev City, consent for an HIV test is required from all individuals aged 14 years and over, those under the age of 14 require parental consent. LAg Avidity testing was performed on residual samples and no name, address or otherwise identifiable information was available in the analysis file. Only adults (≥16years) were included within the study, age categories were defined in the project protocol, which was reviewed and received ethics approval, no persons under the age of 16 years were included within the study. Patients did not experience any additional procedures and no additional consent was sought. The short anonymous questionnaire was introduced as routine surveillance to be completed at the time of testing by the clinic attendee using a handheld electronic tablet. A short explanation about the questionnaire was provided and patients consented by completing the questionnaire. If patients did not consent they could terminate the session.

Data Management {#sec008}
---------------

Data were captured by a remote secure server and downloaded for analysis. Records were de-duplicated using year of birth, sex, clinic and identification number, with discrepancies sent back to the laboratory. The identification number was used to match the person's data with their HIV test result. All records with incomplete information (year of birth, sex and date of diagnosis) or where a previous HIV test was positive, and, therefore, where the diagnosis was not a new one, were removed. Data are presented for persons aged 16 years and over by age quartiles.

Probable route of exposure was determined based on the attendee's answer to the following questions: ever injected drugs, ever had sex with a person of the opposite sex, ever had sex with a person of the same sex, ever paid for sex, and ever been paid for sex. Persons with more than one reported risk factor were classified by the following hierarchical order: PWID, MSM, then heterosexual contact. Additional information was available on sexual behaviour (ever paid for sex, ever been paid for sex or partner of a PWID).

Reason for test was grouped into the following three categories: clinical indication (persons presenting with symptoms), high risk population (those regarded to engage in high risk behaviour i.e. injecting drugs, contact of a known HIV-positive person, those diagnosed with a sexually transmitted infection, those who experienced an occupational HIV risk, and those reporting sex with multiple partners), and general screening (before surgical interventions, recruitment in to the army, prisoners and persons requiring an HIV test due to regulations or policy, e.g. for employment or visa procurement). Persons with more than one reported reason for test were classified by the following hierarchical order: general screening, clinical indication, and high risk population.

Persons were classified as repeat testers if there was evidence of at least one previous negative HIV test. Persons were excluded if the previous test was within a month of the current test, if the previous test result was not reported or was equivocal, or if no previous test date was reported.

Rates per 100,000 population were calculated for HIV tests and HIV diagnoses. Region specific denominators for Kiev City were based on data collected through the government census \[[@pone.0137062.ref017]\].

Population data for MSM, were based on work by the AIDS Alliance \[[@pone.0137062.ref014]\] and the European MSM internet survey (EMIS) \[[@pone.0137062.ref013]\]. The AIDS Alliance used the method of 'anonymous friend', whereby persons were asked to list the behaviours of friends, as well as data from behaviour studies conducted among at risk populations and sociological surveys. EMIS estimated population rates using the diagnosis rate for the Ukraine, the number of survey members, and those survey members diagnosed with HIV.

Statistical Analysis {#sec009}
--------------------

Descriptive statistics are given for persons presenting for an HIV test. Using logistic regression models, we investigated the effect of the following variables on being a repeat tester: age, sex, residence (Kiev City, Outside Kiev City), probable route of exposure (heterosexual, MSM, PWID) and reason for test (clinical indicators, general public screening, high risk behaviour). Two-way interactions were examined.

Statistical analyses were performed using STATA version 13 (STATA Corp, College Station, TX, USA). Only samples from individuals aged 16 years and over were included in analysis.

Results {#sec010}
=======

During the 12-month period April 2013 --March 2014, 6402 persons were tested for HIV. Thirty-two were excluded as follows: 7 records were missing year of birth, sex or identification number, and 25 persons were already known to be HIV positive.

The remaining 6370 tests (3425 in men and 2945 in women) gave a crude test rate of 293.2 per 100,000 population (aged ≥16 years) ([Table 1](#pone.0137062.t001){ref-type="table"}). The median age at test was 30 years (IQR: 26--36), with the majority seeking testing due to symptoms. HIV test results could not be linked for 353 persons. Of the remaining 6017 tests with a result, 467 (7.8%) were HIV positive, equivalent to a diagnosis rate of 21.5 per 100,000 persons ([Table 1](#pone.0137062.t001){ref-type="table"}). The completion rate for questionnaires was 99.4% with only 39 persons not providing any further information.

10.1371/journal.pone.0137062.t001

###### HIV testing and diagnosis rates (per 100,000 population) for persons seeking testing April 2013-- March 2014 in Kiev City, Ukraine.

![](pone.0137062.t001){#pone.0137062.t001g}

  Characteristics                Population \[[@pone.0137062.ref017]\]   Number requesting HIV test [\*](#t001fn001){ref-type="table-fn"}   HIV testing rate   Number newly diagnosed with HIV   Rate of New diagnoses
  ----------------- ------------ --------------------------------------- ------------------------------------------------------------------ ------------------ --------------------------------- -----------------------
  **Total**                      2,172,448                               6370                                                               293.2              467                               21.5
  **Age (years)**   **16--25**   484,839                                 1466                                                               302.4              64                                13.2
                    **26--30**   212,340                                 1795                                                               845.3              120                               56.5
                    **31--35**   177,968                                 1456                                                               818.1              154                               86.5
                    **≥36**      1,297,301                               1653                                                               127.4              129                               9.9
  **Sex**           **Male**     990,412                                 3425                                                               345.8              303                               30.6
                    **Female**   1,182,036                               2945                                                               249.1              164                               13.9

\* Excluding 32 persons: 7 records were missing year of birth, sex or identification number, and 25 persons were already known to be HIV positive.

Probable route of exposure to HIV was available for 5986 of the 6017 (99.5%) individuals with a test result, the majority (4803; 80.2%) of whom reported heterosexual contact, with 191 (3.2%) identifying as MSM. Of the 4803 reporting heterosexual contact, 519 (10.8%) reported contact with PWIDs, with a higher proportion for women (417/2587, 16.1%) compared to men (101/2216, 4.6%). A further 377 (7.8%) reported paying for sex or reported that they themselves were paid for sex.

The median age among those newly-diagnosed was higher than those testing (32 years; IQR: 28--36), and HIV prevalence among those tested was highest among persons aged 31--35 years, males, PWID and MSM ([Table 2](#pone.0137062.t002){ref-type="table"}). The diagnosis rate for PWID was estimated at 760.7 per 100,000 PWID and, for MSM, ranged from 516.3 to 1548.3 per 100,000 MSM. The proportion of persons newly-diagnosed among those in the heterosexual contact exposure category was low and similar for men and women. For PWID, the proportion newly-diagnosed was somewhat higher for women compared with men (21.5% vs. 17.1% respectively).

10.1371/journal.pone.0137062.t002

###### Distribution of all persons testing for HIV and persons newly diagnosed at any one of the four HIV testing sites between April 2013 --March 2014 in Kiev City, Ukraine.
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                                                                         Number tested for HIV   Number where test result available   Newly Diagnosed   
  ---------------------------------------------------------------------- ----------------------- ------------------------------------ ----------------- ------
  **Age (years)**                                                                                                                                       
  ≤25                                                                    1466                    1381                                 64                4.6
  26--30                                                                 1795                    1698                                 120               7.1
  31--35                                                                 1456                    1376                                 154               11.2
  ≥36                                                                    1653                    1562                                 129               8.3
  **Sex**                                                                                                                                               
  Male                                                                   3425                    3224                                 303               9.4
  Female                                                                 2945                    2793                                 164               5.9
  **Residence**                                                                                                                                         
  Kiev (city)                                                            5771                    5457                                 391               7.2
  Kiev area (small town)                                                 412                     384                                  53                13.8
  Kiev area (village)                                                    111                     108                                  10                9.3
  Another area of Ukraine                                                46                      43                                   7                 16.3
  Not Reported                                                           30                      25                                   6                 
  **Probable route of exposure** [\*](#t002fn001){ref-type="table-fn"}                                                                                  
  Persons who inject drugs: Male                                         835                     801                                  137               17.1
  Persons who inject drugs: Female                                       198                     191                                  41                21.5
  Men who have sex with men                                              201                     191                                  46                24.1
  Heterosexual contact: Male                                             2370                    2216                                 114               5.1
  Heterosexual contact: Female                                           2728                    2587                                 122               4.7
  Not reported                                                           38                      31                                   7                 
  **Testing history**                                                                                                                                   
  Repeat tester                                                          1413                    1365                                 84                6.2
  First-time tester                                                      4787                    4499                                 349               7.8
  Not Reported                                                           170                     153                                  34                
  **Reason for test** [\*](#t002fn001){ref-type="table-fn"}                                                                                             
  Clinical Indicators                                                    3166                    2336                                 257               11.0
  High Risk Behaviour                                                    2427                    2977                                 163               5.5
  General Public Screening                                               735                     668                                  40                6.0
  Not Reported                                                           42                      36                                   7                 

\* Persons with more than one reported risk factor were classified by the following hierarchical order: PWID, MSM, then heterosexual contact. Persons with more than one reported reason for test were classified by the following hierarchical order: general Screening, clinical indication, then high risk population.

^**≠**^ Excluding 32 persons: 7 records were missing year of birth, sex or identification number, and 25 persons were already known to be HIV positive.

For 6200 individuals, information on testing history was available, of whom 1413 (23%) were identified as repeat testers. In univariate logistic regression models, repeat testers were more likely to be older, MSM or PWID, and where reason for test was high risk behaviour, compared with first time testers ([Table 3](#pone.0137062.t003){ref-type="table"}). As the interaction between sex and probable route of exposure was found to be significant (p = 0.004), we re-categorised these two variables to create a new variable (MSM, female heterosexual contact, male heterosexual contact, female PWID, and male PWID).

10.1371/journal.pone.0137062.t003

###### Factors associated with repeat testing among persons attending for an HIV test April 2013-- March 2014 in Kiev City, Ukraine.

![](pone.0137062.t003){#pone.0137062.t003g}

                                   Univariate          Multivariate[\*](#t003fn001){ref-type="table-fn"}                       
  -------------------------------- ------------------- --------------------------------------------------- ------------------- ---------
  **Age (per 10 year increase)**   1.21 (1.12--1.30)   \<0.001                                             1.28 (1.19--1.39)   \<0.001
  **Area of residence**                                                                                                        
  Kiev City                        1                                                                       1                   
  Outside Kiev City                0.67 (0.54--0.85)   \<0.001                                             0.66 (0.52--0.84)   \<0.001
  **Probable route of exposure**                                                                                               
  Heterosexual contact: Female     1                                                                       1                   
  Heterosexual contact: Male       0.81 (0.70--0.93)                                                       0.78 (0.68--0.91)   
  MSM                              2.16 (1.59--2.93)   \<0.001                                             1.87 (1.37--2.55)   \<0.001
  PWID: Female                     1.52 (1.09--2.12)                                                       1.40 (1.00--1.96)   
  PWID: Male                       2.10 (1.77--2.50)                                                       1.93 (1.62--2.30)   
  **Reason for test**                                                                                                          
  Clinical Indicators              1                                                                       1                   
  General Pubic Screening          0.25 (0.19--0.34)   \<0.001                                             0.28 (0.20--0.38)   \<0.001
  High Risk Behaviour              1.52 (1.34--1.72)                                                       1.55 (1.37--1.76)   

\* Adjusted for all other factors in table.

After adjusting for all other variables, probable route of exposure/sex remained an independent predictor for repeat testing. Compared to heterosexual women, MSM \[Odds Ratio (OR): 1.87; 95% Confidence Interval (CI):1.37--2.55\] and PWIDs (males and females) \[OR = 1.93; 95% CI:1.62--2.30 and OR = 1.40; 95% CI:1.00--1.96, respectively\] were more likely to repeat test, and heterosexual men were less likely to repeat test \[OR = 0.78; 95% CI:0.68--0.91\].

Furthermore, repeat testing was significantly more likely with increasing age \[OR = 1.28 per 10 year increase, 95% CI:1.19--1.39\] and among those engaging in high risk behaviour \[OR = 1.55; 95% CI:1.37--1.76\] compared with those testing due to clinical indicators. Repeat testing was less likely among those testing as part of screening \[OR = 0.28; 0.20--0.38\] and those resident outside the City \[OR = 0.66; 95% CI:0.52--0.84\] ([Table 3](#pone.0137062.t003){ref-type="table"}).

Heterosexual women reporting high risk behaviour (high risk partner or sex work) had a higher proportion of repeat testers than heterosexual men overall (25%; 135/539 vs. 19%; 72/374), predominately led by women with partners who inject drugs (28%; 119/420).

Discussion {#sec011}
==========

We estimate an HIV prevalence of 7.8% for persons presenting for an HIV test in Kiev City, equivalent to 21.5 diagnoses per 100,000 population, and an overall testing rate of 293.2 per 100,000 population. For the first time detailed information on HIV risk behaviour was available, indicating that MSM and PWIDs were disproportionately affected by HIV. Furthermore, given the proportions among newly-diagnosed female heterosexuals reporting sexual contact with PWID there is further evidence of bridging in risk between PWID and their sexual partners.

Although, the diagnosis rate of 21.5 per 100,000 population in Kiev City is lower than that for Ukraine as a whole (37.1 per 100,000), it is however, substantially higher than rates for Western and Central Europe (6.6/100,000 and 2.1/100,000)\[[@pone.0137062.ref001]\]. Using MSM population estimates \[[@pone.0137062.ref013], [@pone.0137062.ref018]\], the diagnosis rate for MSM ranged from 490.6/100,000 to 1548.3/100,000. This is substantially higher than the diagnosis rates of 76.6 to 241.7/100,000 suggested by the 152 MSM diagnosed in Ukraine overall \[[@pone.0137062.ref001]\], though the prevalence of MSM may differ between Kiev and the rest of Ukraine.

Interestingly, there was little difference in the diagnosis rates between men and women reporting heterosexual contact. Given the high rates of stigma and discrimination within Ukraine we had anticipated non-disclosure of homosexuality to be high, with men more likely to report sex with women, leading to high HIV diagnosis rate in heterosexual men compared to heterosexual women. However, this was not reflected in the data, suggesting that any non-disclosed homosexuality among men is unlikely to be substantial. However, in agreement with previous findings, our data suggest a bridging between high risk individuals and the heterosexual population with an estimated 1 in 6 heterosexual women reporting contact with a PWID \[[@pone.0137062.ref008]\].

Furthermore, our data indicate an increasing number of women being diagnosed with HIV, particularly women who inject drugs who are at a higher risk as they are more likely to be second on the needle, exchange sex for drugs, subject to gender-based violence and stigma, and have unsafe sex with an injecting partner \[[@pone.0137062.ref019]--[@pone.0137062.ref021]\].

Testing patterns among persons presenting for an HIV test in Kiev City are consistent with the previous literature \[[@pone.0137062.ref022]--[@pone.0137062.ref027]\], where those at high risk of HIV were more likely to frequently test, both probable route of exposure (MSM and PWID) and reason for test (high risk behaviour) were independently associated with repeat testing. Age was also associated with repeat testing, which may, in part, be due to younger persons having had less time to test than those who are older. Around one in three MSM and PWID reported a previous test compared to one in five among heterosexuals, indicating that persons at risk have some awareness about testing; this was also evident among heterosexual women with partners who inject drugs.

It is important to bear in mind that data from Kiev City may well not be representative for the whole of Ukraine, particularly for regions with a lower HIV prevalence such as Chernivtsi, Ternopilm and Transcarpathian, and our findings may not be generalizable to the rest of the country. For a better understanding of the epidemic in other regions, we believe it would be beneficial to consider implementation of our methods across Ukraine. Acceptance rate was high (\>99%) among attenders and information on HIV risk behaviour was also available for \>99% of those completing the questionnaire. Population data for MSM was estimated using the published literature, based on work by the AIDS Alliance \[[@pone.0137062.ref014]\] or through the use of the European MSM internet survey (EMIS) \[[@pone.0137062.ref013]\]. There are definite uncertainties within these estimates, indicated by the range, and with both dependent on self-reported information, and further work is needed to establish the true numbers at risk.

This study provides more detailed information on persons testing and those newly diagnosed with HIV in Kiev City than had previously been available. It highlights the impact key populations have on the epidemic, feeding into current work on HIV prevention and response. We have shown that persons were comfortable with disclosing their risk, in particular men identifying as MSM. Diagnosis rates among MSM for Kiev City suggest that there may be a significant level of undisclosed homosexuality overall in Ukraine \[[@pone.0137062.ref009]\], further supporting work to minimise stigma and discrimination.
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